PNAS:c-Myc-SIRT1通道是癌细胞无限分裂的分子机制

2012-01-06 MedSci原创 MedSci原创

近日,国际著名杂志PNAS刊登了德国慕尼黑大学等机构的研究人员的最新研究成果“The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop。”,文章中,研究人员揭示了癌细胞无限分裂的一种分子机制。 癌细胞最显著

近日,国际著名杂志PNAS刊登了德国慕尼黑大学等机构的研究人员的最新研究成果“The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop。”,文章中,研究人员揭示了癌细胞无限分裂的一种分子机制。

癌细胞最显著的特征就是无限分裂、永不停止,而正常细胞则不会无限生长。什么原因导致癌细胞的“疯狂”?德国研究人员最新发现,一种核蛋白和一种酶会在癌细胞中“狼狈为奸”,形成反馈回路,助长癌细胞无限分裂。

德国慕尼黑大学的研究人员发现,这是因为一种名为c-Myc的核蛋白可摆脱细胞内的控制机制,促使癌细胞分裂。这种蛋白可调节细胞的生长和分裂,合成这种蛋白的基因本应在造血、胚胎发育等情况下“工作”,在不需要时受细胞抑制而“休息”。但是,在癌细胞中这种基因却摆脱抑制、放肆表达,在淋巴癌、乳腺癌等癌症中甚至扮演了“制造者”的角色。

研究人员发现,高度聚集的c-Myc蛋白可激活一种抑制细胞衰老和死亡的酶SIRT1,而这种酶又可反作用于c-Myc蛋白,如此形成一个回路,令c-Myc蛋白和SIRT1酶越来越多,最终促使癌细胞无限分裂。

研究人员表示,发现这一反馈回路有助于研究治疗癌症的新方法。用药物等手段阻断这一回路中的某个或某几个环节,或许可以抑制癌细胞分裂。(生物谷Bioon.com)

The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop

Antje Menssena,1, Per Hydbringb,2,3, Karsten Kapellec,2, Jörg Vervoortsc, Joachim Dieboldd, Bernhard Lüscherc, Lars-Gunnar Larssonb, and Heiko Hermekinga,1

Silent information regulator 1 (SIRT1) represents an NAD+-dependent deacetylase that inhibits proapoptotic factors including p53. Here we determined whether SIRT1 is downstream of the prototypic c-MYC oncogene, which is activated in the majority of tumors. Elevated expression of c-MYC in human colorectal cancer correlated with increased SIRT1 protein levels. Activation of a conditional c-MYC allele induced increased levels of SIRT1 protein, NAD+, and nicotinamide-phosphoribosyltransferase (NAMPT) mRNA in several cell types. This increase in SIRT1 required the induction of the NAMPT gene by c-MYC. NAMPT is the rate-limiting enzyme of the NAD+ salvage pathway and enhances SIRT1 activity by increasing the amount of NAD+. c-MYC also contributed to SIRT1 activation by sequestering the SIRT1 inhibitor deleted in breast cancer 1 (DBC1) from the SIRT1 protein. In primary human fibroblasts previously immortalized by introduction of c-MYC, down-regulation of SIRT1 induced senescence and apoptosis. In various cell lines inactivation of SIRT1 by RNA interference, chemical inhibitors, or ectopic DBC1 enhanced c-MYC-induced apoptosis. Furthermore, SIRT1 directly bound to and deacetylated c-MYC. Enforced SIRT1 expression increased and depletion/inhibition of SIRT1 reduced c-MYC stability. Depletion/inhibition of SIRT1 correlated with reduced lysine 63-linked polyubiquitination of c-Myc, which presumably destabilizes c-MYC by supporting degradative lysine 48-linked polyubiquitination. Moreover, SIRT1 enhanced the transcriptional activity of c-MYC. Taken together, these results show that c-MYC activates SIRT1, which in turn promotes c-MYC function. Furthermore, SIRT1 suppressed cellular senescence in cells with deregulated c-MYC expression and also inhibited c-MYC–induced apoptosis. Constitutive activation of this positive feedback loop may contribute to the development and maintenance of tumors in the context of deregulated c-MYC.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1855232, encodeId=f62518552321e, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sun Jul 15 08:29:00 CST 2012, time=2012-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251839, encodeId=870f1251839e1, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sun Jan 08 14:29:00 CST 2012, time=2012-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274778, encodeId=746912e477813, content=<a href='/topic/show?id=1bbc12404ba' target=_blank style='color:#2F92EE;'>#MYC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12404, encryptionId=1bbc12404ba, topicName=MYC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Jan 08 14:29:00 CST 2012, time=2012-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530294, encodeId=2844153029427, content=<a href='/topic/show?id=2c9738e9d2' target=_blank style='color:#2F92EE;'>#c-myc#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3879, encryptionId=2c9738e9d2, topicName=c-myc)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d3b12082233, createdName=lixiaol, createdTime=Sun Jan 08 14:29:00 CST 2012, time=2012-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551910, encodeId=56761551910cc, content=<a href='/topic/show?id=0cb91634355' target=_blank style='color:#2F92EE;'>#sirt1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16343, encryptionId=0cb91634355, topicName=sirt1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Jan 08 14:29:00 CST 2012, time=2012-01-08, status=1, ipAttribution=)]
    2012-07-15 drwjr
  2. [GetPortalCommentsPageByObjectIdResponse(id=1855232, encodeId=f62518552321e, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sun Jul 15 08:29:00 CST 2012, time=2012-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251839, encodeId=870f1251839e1, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sun Jan 08 14:29:00 CST 2012, time=2012-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274778, encodeId=746912e477813, content=<a href='/topic/show?id=1bbc12404ba' target=_blank style='color:#2F92EE;'>#MYC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12404, encryptionId=1bbc12404ba, topicName=MYC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Jan 08 14:29:00 CST 2012, time=2012-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530294, encodeId=2844153029427, content=<a href='/topic/show?id=2c9738e9d2' target=_blank style='color:#2F92EE;'>#c-myc#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3879, encryptionId=2c9738e9d2, topicName=c-myc)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d3b12082233, createdName=lixiaol, createdTime=Sun Jan 08 14:29:00 CST 2012, time=2012-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551910, encodeId=56761551910cc, content=<a href='/topic/show?id=0cb91634355' target=_blank style='color:#2F92EE;'>#sirt1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16343, encryptionId=0cb91634355, topicName=sirt1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Jan 08 14:29:00 CST 2012, time=2012-01-08, status=1, ipAttribution=)]
    2012-01-08 yxch36
  3. [GetPortalCommentsPageByObjectIdResponse(id=1855232, encodeId=f62518552321e, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sun Jul 15 08:29:00 CST 2012, time=2012-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251839, encodeId=870f1251839e1, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sun Jan 08 14:29:00 CST 2012, time=2012-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274778, encodeId=746912e477813, content=<a href='/topic/show?id=1bbc12404ba' target=_blank style='color:#2F92EE;'>#MYC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12404, encryptionId=1bbc12404ba, topicName=MYC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Jan 08 14:29:00 CST 2012, time=2012-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530294, encodeId=2844153029427, content=<a href='/topic/show?id=2c9738e9d2' target=_blank style='color:#2F92EE;'>#c-myc#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3879, encryptionId=2c9738e9d2, topicName=c-myc)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d3b12082233, createdName=lixiaol, createdTime=Sun Jan 08 14:29:00 CST 2012, time=2012-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551910, encodeId=56761551910cc, content=<a href='/topic/show?id=0cb91634355' target=_blank style='color:#2F92EE;'>#sirt1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16343, encryptionId=0cb91634355, topicName=sirt1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Jan 08 14:29:00 CST 2012, time=2012-01-08, status=1, ipAttribution=)]
    2012-01-08 guihongzh
  4. [GetPortalCommentsPageByObjectIdResponse(id=1855232, encodeId=f62518552321e, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sun Jul 15 08:29:00 CST 2012, time=2012-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251839, encodeId=870f1251839e1, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sun Jan 08 14:29:00 CST 2012, time=2012-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274778, encodeId=746912e477813, content=<a href='/topic/show?id=1bbc12404ba' target=_blank style='color:#2F92EE;'>#MYC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12404, encryptionId=1bbc12404ba, topicName=MYC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Jan 08 14:29:00 CST 2012, time=2012-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530294, encodeId=2844153029427, content=<a href='/topic/show?id=2c9738e9d2' target=_blank style='color:#2F92EE;'>#c-myc#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3879, encryptionId=2c9738e9d2, topicName=c-myc)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d3b12082233, createdName=lixiaol, createdTime=Sun Jan 08 14:29:00 CST 2012, time=2012-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551910, encodeId=56761551910cc, content=<a href='/topic/show?id=0cb91634355' target=_blank style='color:#2F92EE;'>#sirt1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16343, encryptionId=0cb91634355, topicName=sirt1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Jan 08 14:29:00 CST 2012, time=2012-01-08, status=1, ipAttribution=)]
    2012-01-08 lixiaol
  5. [GetPortalCommentsPageByObjectIdResponse(id=1855232, encodeId=f62518552321e, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sun Jul 15 08:29:00 CST 2012, time=2012-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251839, encodeId=870f1251839e1, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sun Jan 08 14:29:00 CST 2012, time=2012-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274778, encodeId=746912e477813, content=<a href='/topic/show?id=1bbc12404ba' target=_blank style='color:#2F92EE;'>#MYC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12404, encryptionId=1bbc12404ba, topicName=MYC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Jan 08 14:29:00 CST 2012, time=2012-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530294, encodeId=2844153029427, content=<a href='/topic/show?id=2c9738e9d2' target=_blank style='color:#2F92EE;'>#c-myc#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3879, encryptionId=2c9738e9d2, topicName=c-myc)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d3b12082233, createdName=lixiaol, createdTime=Sun Jan 08 14:29:00 CST 2012, time=2012-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551910, encodeId=56761551910cc, content=<a href='/topic/show?id=0cb91634355' target=_blank style='color:#2F92EE;'>#sirt1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16343, encryptionId=0cb91634355, topicName=sirt1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Jan 08 14:29:00 CST 2012, time=2012-01-08, status=1, ipAttribution=)]
    2012-01-08 quxin068

相关资讯

ASCO年度报告:2011临床肿瘤学重大进展之乳腺癌

 AI预防乳腺癌价值获证明   安慰剂对照、双盲乳房预防试验3(NCIC CTG MAP.3)纳入了4560名年龄≥60岁且处于乳腺癌高发危险的绝经后女性。中位随访3年的结果发现,服用芳香化酶抑制剂(AI)依西美坦组女性侵袭性乳腺癌年发生率降低了65%(0.19%对0.55%,P=0.002),同时,癌前病变——导管原位癌的发生率也显著降低;两组临床骨折、骨质疏松症、高胆固醇血症或心血管事件的

Oncotarget:石胆酸能杀死癌细胞但不伤害健康细胞

(LCA抗肿瘤的机制模型:a. 细胞系BE(2)-m17. b. 细胞系SK-n-MCIXC) 2012年1月4日,据《每日科学》报道,在消化过程中由肝脏自然产生,其作用已被严重低估。发表在Oncotarget期刊上的一项研究表明,LCA可以杀死数种类型的癌细胞,如那些发现于脑肿瘤和乳腺癌中的癌细胞。 该研究小组,由Concordia大学领导,同时包括来自麦吉尔大学、蒙特利尔犹太总医院戴维斯研

PNAS:机械挤压作用促进肿瘤转移

(图片来源:PNAS) 麻省理工学院的Janet M. Tse等近日在《美国国家科学院院刊》(Proceedings of the National Academy of Sciences)发表论文称,机械挤压作用或可促进肿瘤细胞转移。 肿瘤细胞在体内进行不受机体控制的增殖分裂,当其分裂数量到达一定程度后,肿瘤细胞便受到有限的空间带来的挤压。为了研究这种挤压作用对肿瘤细胞的影响,Janet T

Mol. Cell:启动癌细胞对糖嗜好的丙酮酸脱氢酶激酶或为抗癌靶标

癌细胞对糖的渴望,部分上是因为它们关闭它们的线粒体——能够有效燃烧葡萄糖的动力厂——以便偏好一种更加无效率的方式使用葡萄糖。它们获益,因为副产物能够为快速生长的癌细胞提供构建材料。 美国埃默里大学温希普癌症研究所科学家证实很多类型的癌细胞扳动开关让葡萄糖从线粒体转移走。他们的发现提示着促进几种类型癌症生长的酪氨酸激酶在线粒体中发挥的作用要比人们以前所认识的大得多。 这些结果也突出地显示丙酮

Science:皮肤中的免疫细胞可产生化学物质促发癌症

在这个表皮表层里,可见朗格汉斯细胞(绿色)构成一个细胞网络,延长树突状的进程 日前,刊登在最新一期Science上的一篇论文"Langerhans Cells Facilitate Epithelial DNA Damage and Squamous Cell Carcinoma"表明,以能探测到皮肤中的外来入侵物而闻名的一组免疫细胞也能通过代谢环境中的化学物质而促进肿瘤的生长。 包括皮肤及

靶向抗癌治疗方法(斯坦福大学公开课)

靶向抗癌治疗方法(斯坦福大学公开课)